Pierluigi Gazzolo to Leave ViacomCBS Networks International
20.10.2020 15:45:00 EEST | Business Wire | Press release
ViacomCBS Networks International (VCNI), a division of ViacomCBS Inc. (NASDAQ: VIAC), has today confirmed the departure of one of its longest serving executives, Pierluigi Gazzolo, who will step down from his role as President, Streaming and Studios for VCNI at the end of this month to focus on other interests.
During Gazzolo’s tenure as President of Streaming and Studios for VCNI, he successfully established the content proposition, team and go to market strategy for the international launch of Paramount+ and expanded the roadmap for Pluto TV internationally.
VCNI Streaming Leadership
Reporting to David Lynn, President and CEO of VCNI, and working closely with Tom Ryan, President & CEO of ViacomCBS Streaming, Kelly Day, Chief Operating Officer of VCNI, will take over leadership of the division’s streaming business as President of Streaming and COO of VCNI. In this new role, Day will have oversight of the international roll-out of Paramount+, a new premium SVOD service due to launch in 2021 across Australia, Latin America, and the Nordics; as well as the ongoing expansion of Pluto TV, following its successful launch in Latin America.
Regarding Day’s expanded remit, Lynn added, “We are in the fortunate position of going from strength to strength with this transition. With a truly global streaming organization, it’s a pivotal moment in the evolution of our streaming strategy, with the expansion of Paramount+ and Pluto TV, both of which are critical to our future growth. Kelly has an enviable track record of launching and growing streaming businesses and has added a layer of extraordinary digital expertise to our management team in a short space of time. Now, also, working closely with Tom Ryan, I’m confident Kelly will accelerate our transition to becoming a more digitally-led business, while seizing our global streaming opportunity.”
ViacomCBS International Studios Leadership
ViacomCBS Studios International (VIS) will supply original content to the new Paramount+ service in some markets, while continuing to supply scripted, comedy and reality series to VCNI’s free and pay TV networks as well as third party streamers and broadcasters.
Also, reporting to Lynn, JC Acosta, who oversees VCNI’s operations in Latin America and Canada as President, VCN Americas, will take on additional responsibility as President, ViacomCBS International Studios.
Lynn added, “One of our biggest achievements in recent years has been the formation and expansion of VIS, which really couldn’t have happened without Pier’s vision. In the past year, under Pier’s leadership he doubled the global development slate, setting VCNI up for continued global success in the studios arena.”
“Now with JC’s expertise in production and development, coupled with his drive and dedication its incredibly reassuring that JC will take over leadership of VIS,” said Lynn. “Given JC’s intimate understanding of our Studios business, his connections and his knowledge of the international content market, we couldn’t be better positioned for continued growth.”
Gazzolo’s Tenure
Paying tribute to Gazzolo, Lynn said, “While he will hate to be labelled as a veteran, there’s no better word to describe someone who has dedicated so much of his career to our company and who has benefited it so much with his wisdom and experience. He’s a brilliant all-rounder who has played in many positions for our team, but always with the same outstanding results. It’s typical of Pier’s commitment that he’s stayed to oversee a seamless handover to Kelly and JC, even though he’s been signaling his interest in pursuing his own projects for some time. I can’t thank him enough for his contribution to our business over many years. I know everyone at VCNI will join me in genuinely wishing him well in his future endeavors.”
Gazzolo commented, “I’ve grown up with this amazing company. From MTV Latino, to MTV Networks to Viacom International Media Networks to post merger ViacomCBS Networks International. I’ve been honored to grow and evolve with ViacomCBS, and I’m immensely grateful to have worked across so many regions and divisions at the most dynamic media company in the world. I have benefited tremendously from having worked with unparalleled leaders and mentors, throughout my tenure, but especially in the latest chapter of my term. Most importantly I’ve created wonderful close friendships in my 27 years with the company – and those will continue long after I leave the building.”
About Pierluigi Gazzolo
Prior to taking up his current role as President, Streaming and Studios in November 2019, Pierluigi Gazzolo was President, Americas for Viacom International Media Networks, which was renamed as VCNI after the ViacomCBS merger in December last year.
Based in Miami, he oversaw a marked expansion of the company’s operations across Spanish-speaking Latin America and Brazil, spearheaded by two key acquisitions – ownership of Argentina’s leading free-to-air broadcaster, Telefe (2016), and a majority stake in Brazilian comedy producer, Porta dos Fundos (2017). Combining Telefe’s studios business and Porta dos Fundos with VIMN’s existing production activities in the region, Gazzolo formed VIS and secured its first sales to both Netflix and Amazon Prime, as well as a host of other deals with broadcasters and streamers across the region. Under his leadership, VIS has expanded its production activities in the UK, Europe, and Asia.
At the same time as leading the company’s operations in Latin America, Gazzolo continued to lead Nickelodeon internationally, giving him oversight of this critical brand in all markets outside the U.S. In this role, he oversaw an increase in international supply to Nickelodeon’s global content pipeline with locally developed shows being remade for global distribution, including Talia in the Kitchen and Every Witch Way.
Previously, Gazzolo was Chief Operating Officer for VIMN (2011 to 2014) and its predecessor MTV Networks International (2009 to 2011), reporting in both roles to Bob Bakish, who is now CEO, ViacomCBS Inc. Before 2009, he held several different roles with the company including serving as President of MTV Networks Latin America.
ViacomCBS Networks International:
ViacomCBS Networks International, a unit of ViacomCBS Inc. (NASDAQ: VIAC), comprises many of the world’s most iconic entertainment brands, including Network 10, Channel 5, Telefe, Viacom 18, ViacomCBS International Studios, Nickelodeon, MTV, Comedy Central, BET, Paramount Network and Pluto TV. In addition to offering innovative streaming services and digital video products, ViacomCBS Networks International provides powerful capabilities in production, distribution and advertising solutions for partners on five continents and across more than 180 countries.
VIAC-IR
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005683/en/
Contact information
Press
Kate Laverge
Senior Vice President, Communications, ViacomCBS Networks International
kate.laverge@viacom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
